Novo Nordisk rejects diabetes drug Victoza complaint

<p>COPENHAGEN (Reuters) – Danish drugmaker <span>Novo Nordisk</span> deserted a <span>consumer advocacy group</span>‘s censure about a big-selling <span>diabetes drug Victoza</span> as illogical and pronounced it did not design U.S. regulators to take any action.</p>
<p> Its shares primarily forsaken some-more than 2 percent in sprightly trade on Friday after non-profit organisation <span>Public Citizen</span> asked a <span>U.S. Food and Drug Administration</span> (<span>FDA</span>) to repel capitulation of Victoza.</p>
<p> Novo Nordisk, a world’s biggest writer of insulin used to provide diabetes, was a most-traded batch on a Copenhagen bourse, with some-more than 350 million <span>Danish crowns</span> ($61.8 million) value changing hands.</p>
<p> Public Citizen pronounced on Thursday that Victoza increases a risk of criti...